Possible solution to reveal subjects with asymptomatic atherosclerosis and enhanced vasodilatation due to COVID-19

COVID-19 Solution

The Arteriograph method and apparatus is a patented technology for measuring peripheral and central hemodynamic parameters non-invasively. The device measures aortic pulse wave velocity, which is an index of the aortic stiffness and underlying atherosclerosis, according to the recent ESC/ESH Guidelines for the management of arterial hypertension. Consequently, in case of measuring increased aortic pulse wave velocity we may conclude that the patient has atherosclerosis (most probably asymptomatic), thus, according to the formerly mentioned scientific data the ACE2 level is up-regulated, therefore the patient has higher risk for SARS-CoV-2 virus infection.

Furthermore, the Arteriograph device measures the augmentation index. This parameter is tightly connected to the actual peripheral vasodilatory or vasoconstrictive status maintained by the small arteries and arterioles. Taking into consideration that the ACE2 up-regulation causes vasodilation in different cardiovascular diseases, the decreased augmentation index, measured by Arteriograph might reveal those whose ACE2 is up-regulated and are at higher risk for SARS-CoV-2 infection.

Can this technology be used in SARS-CoV-2 virus epidemic?


Yes. The Arteriograph method and device uses only a single upper arm cuff and the measurement is completely automatic, user-independent. The examination (even self-examination) can easily be performed in home conditions. The whole examination needs 2 minutes. The measured data can be transferred to remote evaluation centers via internet. The device can be operated by any PC, laptop or tablet with Microsoft operational system, which are usually available most patients’ home.

Before and after use, the device and the cuff can be disinfected by a detergent spray.